Edoxaban, Rivaroxaban, or Apixaban for Cancer-Associated Venous Thromboembolism in the Real World: Insights from the COMMAND VTE Registry-2.

Daisuke SuetaYugo YamashitaTakeshi MorimotoRyuki ChataniYuji NishimotoKazuhisa KanedaNobutaka IkedaYohei KobayashiSatoshi IkedaKitae KimMoriaki InokoToru TakaseShuhei TsujiMaki OiTakuma TakadaKazunori OtsuiJiro SakamotoYoshito OgiharaTakeshi InoueShunsuke UsamiPo-Min ChenKiyonori TogiNorimichi KoitabashiSeiichi HiramoriKosuke DoiHiroshi MabuchiYoshiaki TsuyukiKoichiro MurataKensuke TakabayashiHisato NakaiWataru ShioyamaTomohiro DohkeRyusuke NishikawaTakeshi KimuraKenichi Tsujitanull null

Published in: Thrombosis and haemostasis (2024)

The risks of recurrent VTE and all-cause death did not differ significantly among the different DOACs ; however, the risk of bleeding events could differ, with a potentially lower risk of bleeding with rivaroxaban.

Keyphrases

venous thromboembolism
direct oral anticoagulants
atrial fibrillation
human health
risk assessment
pulmonary embolism